Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 215

Similar articles for PubMed (Select 14711810)

1.

Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2.

Tikhomirov O, Carpenter G.

J Biol Chem. 2004 Mar 26;279(13):12988-96. Epub 2004 Jan 7.

2.

Sustained mitogen-activated protein kinase activation is induced by transforming erbB receptor complexes.

Wu CJ, Qian X, O'Rourke DM.

DNA Cell Biol. 1999 Oct;18(10):731-41.

PMID:
10541432
3.

Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK.

Cuadrado A, Garcia-Fernandez LF, Gonzalez L, Suarez Y, Losada A, Alcaide V, Martinez T, Fernandez-Sousa JM, Sanchez-Puelles JM, Munoz A.

J Biol Chem. 2003 Jan 3;278(1):241-50. Epub 2002 Oct 31.

4.

Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.

Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME.

Cancer Res. 2000 Jun 1;60(11):3081-7.

5.

Epidermal growth factor-stimulated intestinal epithelial cell migration requires Src family kinase-dependent p38 MAPK signaling.

Frey MR, Golovin A, Polk DB.

J Biol Chem. 2004 Oct 22;279(43):44513-21. Epub 2004 Aug 16.

6.
7.

p38MAPK acts in the BMP7-dependent stimulatory pathway during epithelial cell morphogenesis and is regulated by Smad1.

Hu MC, Wasserman D, Hartwig S, Rosenblum ND.

J Biol Chem. 2004 Mar 26;279(13):12051-9. Epub 2004 Jan 12.

8.
9.

Exogenous ganglioside GD1a enhances epidermal growth factor receptor binding and dimerization.

Liu Y, Li R, Ladisch S.

J Biol Chem. 2004 Aug 27;279(35):36481-9. Epub 2004 Jun 23.

11.

Epidermal growth factor receptor (EGFR) signaling in cancer.

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS.

Gene. 2006 Jan 17;366(1):2-16. Epub 2005 Dec 27. Review.

PMID:
16377102
12.

erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.

Ethier SP, Kokeny KE, Ridings JW, Dilts CA.

Cancer Res. 1996 Feb 15;56(4):899-907.

13.

ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation.

Hsieh SS, Malerczyk C, Aigner A, Czubayko F.

Int J Cancer. 2000 Jun 1;86(5):644-51.

PMID:
10797285
15.

Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells.

Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP, Ethier SP.

Oncogene. 2005 Apr 28;24(19):3177-86.

PMID:
15735691
16.

Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells.

McCubrey JA, Shelton JG, Steelman LS, Franklin RA, Sreevalsan T, McMahon M.

Oncogene. 2004 Oct 14;23(47):7810-20.

PMID:
15361836
17.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

18.

Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines.

Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Franklin RA, Bertrand FE, McMahon M, McCubrey JA.

Cell Cycle. 2005 Jun;4(6):822-30. Epub 2005 Jun 7.

PMID:
15917660
19.
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk